29-08-2024 15:25 via wallstreet-online.de

Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules

Absorption improvements appear to continue with DehydraTECH-processed Rybelsus® vs. Rybelsus® tablets even under "fed" conditionsDehydraTECH-treated Rybelsus® does absorb through a mouth-melt product format KELOWNA, BC / ACCESSWIRE / …
Jetzt den vollständigen Artikel lesen
Weiterlesen »